Late-breaking platform presentation showed that BIMZELX® (bimekizumab-bkzx) rapidly achieved and maintained high rates of clinical and health-related quality-of-life responses through four years; six out of ten patients achieved complete skin clearance at Year 4 Responder-analyses…

JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the American Academy of Dermatology 2024 Annual Meeting SAN DIEGO,…

NEW YORK, March 9, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hut 8 Corp. (NASDAQ: HUT) between November 9, 2023 and January 18, 2024, both dates inclusive (the “Class Period”), of the important April 8, 2024 lead…

NEW YORK, March 9, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (NYSE: KIND) (NASDAQ: KVSB) between July 6, 2021 and November 8, 2022, both dates…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.